Minerva Neurosciences traded at $6.33 this Wednesday February 11th, increasing $0.02 or 0.32 percent since the previous trading session. Looking back, over the last four weeks, Minerva Neurosciences gained 46.53 percent. Over the last 12 months, its price rose by 222.96 percent. Looking ahead, we forecast Minerva Neurosciences to be priced at 2.46 by the end of this quarter and at 2.24 in one year, according to Trading Economics global macro models projections and analysts expectations.
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on development and commercialization of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company's lead product candidates are roluperidone (MIN-101), MIN-301, and seltorexant. Roluperidone (MIN-101) is a compound that blocks serotonin, sigma, and a adrenergic receptors that are involved in the regulation of mood, cognition, sleep, and anxiety. The Company is developing roluperidone to treat patients with schizophrenia. Roluperidone is designed to block a specific subtype of serotonin receptor called 5-HT2A. MIN-301 is a soluble recombinant form of the Neuregulin-1b1 (NRG-1b1), protein, for the treatment of Parkinson’s disease and for other neurodegenerative disorders. The Company is developing seltorexant for the treatment of insomnia disorder and adjunctive treatment of major depressive disorder (MDD).